Comparison of Intravitreal Ranibizumab and Bevacizumab Treatment for Retinopathy of Prematurity

Arquivos Brasileiros de Oftalmologia - Brazil
doi 10.5935/0004-2749.20150090
Full Text
Abstract

Available in full text

Date
Authors
Publisher

GN1 Genesis Network

Related search

Late Recurrence of Retinopathy of Prematurity After Treatment With Both Intravitreal Bevacizumab and Laser

Journal of AAPOS
Child HealthOphthalmologyPediatricsPerinatology
2014English

Intravitreal Bevacizumab for Retinopathy of Prematurity in Infants Ineligible for Laser Therapy*

Turkish Journal of Medical Sciences
Medicine
2016English

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2017English

A Lower Dose of Intravitreal Bevacizumab Effectively Treats Retinopathy of Prematurity

Journal of AAPOS
Child HealthOphthalmologyPediatricsPerinatology
2018English

Intravitreal Bevacizumab as Single Drug Therapy for Retinopathy of Prematurity in 12 Patients

Archivos Argentinos de Pediatria
Child HealthPediatricsPerinatology
2014English

Low Dose Versus Conventional Dose of Intravitreal Bevacizumab Injection for Retinopathy of Prematurity: A Case Series With Paired-Eye Comparison

Acta Ophthalmologica
MedicineOphthalmology
2016English

Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab

Retina
MedicineOphthalmology
2017English

Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity

Pediatrics
Child HealthPediatricsPerinatology
2016English

Evidence to Date: Ranibizumab and Its Potential in the Treatment of Retinopathy of Prematurity

Eye and Brain
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy